Navigation Links
Celsion Corporation Provides Business Update
Date:4/23/2013

LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today is providing a business update, including the latest findings from its analysis of clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  Celsion is evaluating ThermoDox® in a Phase III clinical trial for primary liver cancer (the HEAT Study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.

Phase III HEAT Study Data Analysis 

The Company has conducted a comprehensive analysis of the data from the Phase III HEAT Study with key principal investigators, data experts and liver cancer experts.  This follows the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the study's primary endpoint.  Emerging data from the HEAT Study post analysis demonstrates that ThermoDox® markedly improves progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA.  The analysis indicates that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox®.  These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.  This data is subject to further verification and review by the HEAT Study Steering Committee. 

"We have completed a thorough review of the HEAT Study and there is clear evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr. Nicholas Borys , Celsion's Vice President and Chief Medical Officer.  "These data are very exciting and consistent with the mechanism of ThermoDox® activity."

Michael Tardugno , Celsion's Chief Executive Officer, added, "Based on the strength of these findings, the Company will request a meeting with regulatory authorities for guidance on moving forward with our HCC development program.  We plan to disclose the details of the HEAT Study data at upcoming medical meetings and in a peer-reviewed publication.  We will provide updates on these activities when appropriate."

Corporate Restructuring

The Company implemented a restructuring program to lower its operating costs to conserve capital.  The program includes elimination of approximately one-third of Celsion's workforce and the deferral of expenses associated with the Company's Phase II study of ThermoDox® in combination with RFA for the treatment of colorectal liver metastases (The ABLATE Study).  Celsion expects these measures to remain in effect until such time as it finalizes its plans for the continuation of its development program with ThermoDox® in HCC.  Celsion ended the first quarter of 2013 with approximately $46 million in cash and investments.  Ongoing salary costs, net of restructuring costs, are expected to reduce overall operating expenses during the current fiscal year.

"While it is difficult to eliminate positions in our talented and dedicated workforce, this move is necessary to ensure that our costs are adequately aligned with our resources and business strategy," Mr. Tardugno said.  "We are reducing expenses in all areas, but we are doing this with an eye toward limiting the impact on our future development programs for ThermoDox® as well as afford us the opportunity to identify and develop new product candidates."

Engagement of Financial Advisor to Evaluate Acquisition Alternatives

The Company has engaged Cantor Fitzgerald & Co. to conduct a comprehensive review of merger and acquisition opportunities with the goal of identifying novel products with high potential, or companies, for Celsion to acquire.  Strategic alternatives the Company may pursue could include, but are not limited to, continuing its current operating plan, partnering or other collaboration agreements, acquisition of another company's business or assets, or a merger or other strategic transaction.  There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms.  The Company does not intend to disclose developments with respect to this process except as required under applicable securities regulations.

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology.  Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford.  For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion 's periodic reports and prospectuses filed with the Securities and Exchange Commission.  Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact
Jeffrey W. Church
Sr. Vice President – Corporate
Strategy and Investor Relations
609-482-2455
jchurch@celsion.com


'/>"/>
SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Celsion Corporation Announces $15 Million Registered Direct Offering
2. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
5. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
6. Neogen Corporation Announces 2nd Quarter Results Conference Call
7. Luminex Corporation to Present at JP Morgan Healthcare Conference
8. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
9. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
10. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
11. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... California (PRWEB) , ... May 18, 2017 , ... ... team-building activities. The Tapas Cooking Challenge is a two-hour team-building package designed ... delicious menu created by Chef Jodi Abel, which include items, such as Blackened ...
(Date:5/18/2017)... (PRWEB) , ... May 17, ... ... CRO standards with psychonneuroendocrine stress expertise, and further enhances its scientific power ... researcher, Douglas A. Granger, Ph.D., has agreed to join the scientific advisory ...
(Date:5/18/2017)... Mo. (PRWEB) , ... May 17, 2017 , ... ... vessels and equipment for varying industries, including food and dairy, munitions, and pharmaceutical/biotech, ... optimal operator safety and ease of use. The improvement in technology comes on ...
(Date:5/18/2017)... ... 2017 , ... When James Sherley, was notified earlier this year that his company Asymmetrex ... 2017 by The Silicon Review , he was not surprised as others might be. ... but this recognition by Silicon Valley was particularly meaningful. Our selection by ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):